secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2022-10-11T23:59:59+00:00
Accession:  0001104659-22-107409
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics enrolls first patient in Phase 3 TETON 2 study of Tyvaso for IPF
--------------------------------------------------------------------------------

- First patient enrolled in Phase 3 TETON 2 study of Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF).
- Study targets 396 adult IPF patients at sites outside the US and Canada; 52-week treatment evaluating forced vital capacity (FVC).
- Tyvaso is already FDA-approved for PH-ILD but not for IPF without documented pulmonary hypertension.
- TETON program builds on positive FVC impact observed in the INCREASE study of inhaled treprostinil in IPF patients with PH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922107409/0001104659-22-107409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922107409/tm2227915d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-107409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer